

Rec'd PCT/PTO

06 DEC 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Syunsuke OHASHI et al.

Group Art Unit : Not Yet Assigned

Appl. No. : 10/529,692

(U.S. National Stage of PCT/JP03/012502)

I.A. Filed : September 30, 2003

Confirmation No. : 2027

For : PHOSPHOLIPID DERIVATIVE

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Service Window, Mail Stop AMENDMENT  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir :

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98, Applicants hereby bring the following information to the attention of the Examiner in charge of the above-identified application, which includes information cited and discussed in the specification, the International Search Report, and the International Preliminary Examination Report issued in connection with International Patent Application No. PCT/JP03/012502, of which the present application is the U.S. National Stage Application. Copies of the International Search Report in English and Japanese, as well as a copy of the International Preliminary Examination Report in Japanese, were submitted with the application on March 29, 2005, and are not enclosed herewith. A copy of the International Preliminary Examination Report in English is enclosed herewith.

The Examiner is invited to review these materials to inspect the relevance indicated during international examination with respect to the documents cited therein. The following is a list of the cited documents :

Biochimica et Biophysica Acta, 1983, Vol. 761, pp. 142-151. Applicants note that this document is cited on page 1 of the specification of the present application;

Biochemical Pharmacology, 1983, Vol. 32 pp. 3381-3387. Applicants note that this document is cited on page 1 of the specification of the present application;

The Pharmaceutical Society of Japan, the 106<sup>th</sup> Annual Meeting, Summaries of Symposia, 1986, p. 336. Applicants note that this document is cited on pages 1-2 of the specification of the present application;

FEBS Letters, 1987, Vol. 223, pp. 42-46. Applicants note that this document is cited on page 2 of the specification of the present application;

Japanese Laid-Open Patent Publication No. SHO 63-221837, together with an English language abstract of the same. Applicants note that this document is cited on page 2 of the specification of the present application;

Chemical & Pharmaceutical Bulletin, 1990, Vol. 38, pp. 1633-1638. Applicants note that this document is cited on page 2 of the specification of the present application;

Biochimica et Biophysica Acta, 1992, Vol. 1108, pp. 257-260. Applicants note that this document is cited on page 2 of the specification of the present application;

Japanese Laid-Open Patent Publication No. HEI 6-228012, together with an English language abstract of the same. Applicants note that this document is cited on page 2 of the specification of the present application;

Japanese Laid-Open Patent Publication No. HEI 2-163108 together with an English language abstract of the same. Applicants note that this document is cited on page 9 of the specification of the present application;

Japanese Laid-Open Patent Publication No. HEI 9-255740, together with an English language abstract of the same. Applicants note that this document is cited on page 9 of the specification of the present application;

FEBS Letter, Vol. 268, No. 1, pp. 235-237 (1990). Applicants note that this document is cited on page 2 of the specification of the present application;

WO 99/09955 A1, together with patent family member U.S. Patent No. 6,436,905;

WO 00/33817 A1;

Japanese Laid-Open Patent Publication No. HEI 7-268038, together with an English language abstract of the same; and

WO 01/74400 A1, which published as European Patent Publication No. EP 1 279 406, together with patent family member U.S. Patent Application Publication No. 2003/0144247 A1.


Further to 37 C.F.R. §1.98 (a)(2)(ii), copies of the U.S. patent and the U.S. patent application publication are not enclosed herewith. However, if any copies are needed, the Examiner is respectfully requested to contact the undersigned.

Except for U.S. Patent and U.S. Patent Application Publication, copies of the above-noted documents are enclosed together with a duly completed Form PTO-1449. The Examiner is accordingly requested to consider each of these documents, and to make them of record in this application by initialing in the appropriate spaces on the Form PTO-1449. Applicants respectfully request that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.

Applicants note that an Office Action on the merits has not issued in the present application, and thus no fee is believed necessary to ensure consideration of the submitted material.

Should there be any questions, the Examiner is invited to contact the undersigned at the below-listed telephone number.

Respectfully Submitted,  
Syunsuke OHASHI et al.



Bruce H. Bernstein  
Reg. No. 29,027

December 6, 2005  
GREENBLUM & BERNSTEIN, P.L.C.  
1950 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191

Arnold Turk  
Reg. No. 33,094

FORM PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
P27627Application No.  
10/529,692INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)Applicant  
Syunsuke OHASHI et al.I.A. Filing Date  
September 30, 2003Group  
Not Yet Assigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		6 4 3 6 9 0 5	08/20/02	TONGE et al.			
	2003/	0 1 4 4 2 4 7	07/31/03	KUWANO et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	63	- 2 2 1 8 3 7	09/14/88	JAPAN			
	6	- 2 2 8 0 1 2	08/16/94	JAPAN			
	2	- 1 6 3 1 0 8	06/22/90	JAPAN			
	9	- 2 5 5 7 4 0	09/30/97	JAPAN			
	9	9 / 0 9 9 5 5	03/04/99	W.I.P.O.			
	0	0 / 3 3 8 1 7	06/15/00	W.I.P.O.			
	7	- 2 6 8 0 3 8	10/17/95	JAPAN			
		1 2 7 9 4 0 6	01/29/03	E.P.O.		(corresponding to WO 01/74400)	

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1	Biochimica et Biophysica Acta, 1983, Vol. 761, pp. 142-151.
2	Biochemical Pharmacology, 1983, Vol. 32 pp. 3381-3387.
3	The Pharmaceutical Society of Japan, the 106 <sup>th</sup> Annual Meeting Summaries of Symposia, 1986, p. 336..
4	FEBS Letters, 1987, Vol. 223, pp. 42-46.
5	English Language Abstract of JP 63-221837., 1988.
7	Chemical & Pharmaceutical Bulletin, 1990, Vol. 38, pp. 1633-1638.
8	Biochimica et Biophysica Acta, 1992, Vol. 1108, pp. 257-260.
9	English Language Abstract of JP 6-228012., 1994.
10	English Language Abstract of JP 2-163108., 1990.
11	English Language Abstract of JP 9-255740., 1997.
12	FEBS Letter, Vol. 268, No. 1, pp. 235-237 (1990).
13	English Language Abstract of JP 7-268038, 1995.

EXAMINER /Roberto Rabago/

DATE CONSIDERED 09/24/2008

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.